Hideho Okada
University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hideho Okada as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:19 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05478837 · Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated GliomaUniversity of California, San Francisco · terminated · Diffuse Midline Glioma, H3 K27M-Mutant · study chair
- Ph1/Ph2NCT02960230 · H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasSabine Mueller, MD, PhD · completed · Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant · study chair
- Ph1NCT02924038 · A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)Nicholas Butowski · terminated · Glioma, Malignant Glioma, Astrocytoma, Grade II · principal investigator
- Ph1NCT02549833 · Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II GliomaJennie Taylor · completed · Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 7 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Preclinical development of breakthrough immunotherapy for brain tumorsR35NS142982 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $943,253 awarded in 2026Same name and institution; not confirmed by an ID
- Project 3: Novel B-SYNC T cell therapy with CNS-specific expression of CAR as a safe and effective therapy for glioblastomaP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2023 to 2026 · $909,447 awarded in 2026Same name and institution; not confirmed by an ID
- Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastomaU19CA264338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2021 to 2025 · $258,407 awarded in 2025Same name and institution; not confirmed by an ID
- Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2018 to 2025 · $783,609 awarded in 2025Same name and institution; not confirmed by an ID
- Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppressionR01CA222965 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2018 to 2022 · $362,043 awarded in 2022Same name and institution; not confirmed by an ID
- Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade gliomaR21CA233856 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2020 · $173,962 awarded in 2020Grant number is on one of their registry trials
- Novel K27M Mutation-derived Neoantigen for T Cell Therapy in GliomasR01NS096954 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2016 to 2017 · $346,719 awarded in 2017Same name and institution; not confirmed by an ID
- Antigens for Molecularly Targeted Vaccines for Progressive GliomaR21NS093654 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2015 to 2016 · $237,750 awarded in 2016Same name and institution; not confirmed by an ID
- Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cellsR21NS083171 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2014 to 2015 · $396,250 awarded in 2015Same name and institution; not confirmed by an ID
- Novel Immunotherapy of Glioma using miR-17-92 Transfected T CellsR01NS055140 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2007 to 2015 · $346,263 awarded in 2015Same name and institution; not confirmed by an ID
- Phase I Vaccine Study using Brain Tumor Initiating Cells in WHO Grade II GliomasR21CA177787 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2014 to 2015 · $202,051 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in diffuse midline glioma (dipg), ranked by citations from NIH iCite, fetched 2026-11-12 11:19 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.J Clin Invest · 2020103 citationsRCR 4.0